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Abstract
Background: The PLATelet inhibition and patient Outcomes (PLATO) trial showed that 
treatment with ticagrelor reduced the rate of death due to vascular causes, myocardial infarction 
and stroke when compared to clopidogrel in patients with ST-elevation or non-ST-elevation acute 
coronary syndrome (ACS). While the comparative benefit of ticagrelor over clopidogrel increased 
over time, event rates accrued in both groups during the study period. The purpose of our 
biomarker-based exploratory analysis was to determine whether long-term platelet inhibition may 
be associated with platelet adaptation.
Methods: A sample of 4000 participants from the PLATO trial also consented to participate in a 
prospectively designed Biomarker Substudy. Blood samples were procured at baseline, 
immediately prior to hospital discharge and at one month and six months. Markers of platelet 
activity, including platelet count, serum CD40-ligand and soluble P-selectin were analyzed. Mean 
levels were compared at discharge, 1 month and 6 months following study drug initiation – first 
for all patients and subsequently stratified by treatment group. A linear mixed model was used to 
estimate the short-term change rate (baseline to 1 month) and long-term change rate (1 month to 6 
month) for each biomarker. A Cox proportional hazards model was used to calculate hazard ratios 
for each change in biomarker over the two time periods examined: baseline to one month and one 
month to six months.
Results: Prior to randomized treatment (baseline), sCD40 ligand and sP-selectin levels were 
elevated above the normal range of the assay (0.39 ug/L and 33.5 ug/L, respectively). The mean 
level of each biomarker was significantly different at one month compared to baseline (p<0.0001). 
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When stratified by treatment group, at one month patients treated with ticagrelor had a larger 
increase in platelet count compared to those treated with clopidogrel (p<0.0001). Similarly, when 
comparing biomarker levels for all patients at six months with those at one month, each differed 
significantly (p<0.05). There was no significant difference between treatment groups during this 
time period. The rate of change for both platelet count and sP-selectin were significantly different 
between baseline and one month when compared to the one to six-month time period (p<0.0001). 
When comparing treatment groups, the rate of increase in platelets from baseline to one month 
was greater for patients treated with ticagrelor (p<0.0001). This was no longer observed in the one 
to six-month interval. Using a Cox proportional hazard model, the increase in platelet count from 
1 month to 6 months was associated with ischemic-thrombotic events, while sCD40 ligand 
decrease from 1 month to 6 months was associated with hemorrhagic events. There were no 
differences between treatment groups for the associations with clinical endpoints.
Conclusion: Dynamic changes in platelet count, sCD-40 ligand and sP-selectin occur over time 
among patients with ACS. Platelet-directed therapy with a P2Y12 receptor inhibitor in 
combination with aspirin modestly impacts the expression of these biomarkers. Platelet count and 
sCD40 ligand may offer modest overall predictive value for future ischemic-thrombotic or 
hemorrhagic clinical events, respectively. The existence of a platelet adaptome and its overall 
clinical significance among patients at risk for thrombotic events will require a more in-depth and 
platelet-biology specific investigation.
Keywords
Acute Coronary Syndrome; P2Y12 Inhibitor; Ticagrelor; Platelet adaptome
Introduction
Platelets play a fundamental role in hemostasis, preventing blood loss after vascular injury. 
Because of this, the number of platelets within the circulation far exceeds what is necessary 
for day-to-day hemostasis and vascular repair; dynamic systems are in place for adaption to 
heritable or acquired conditions. For example, platelet P2Y12 receptor deficiency is neither 
lethal in utero nor is it associated with a strong bleeding phenotype, suggesting that existing 
redundancies or responses in platelet number, activation potential and/or “platelet 
adaptation” offer host protection. One such redundancy includes the presence of at least two 
distinct ADP receptors, including P2Y12 and P2Y1, that initiate ADP-induced aggregation of 
platelets[1]. Further, patients receiving aspirin have heightened platelet gene expression and 
function of non-cyclooxygenase (COX) 1 pathways within two weeks of initiation[2].
Clopidogrel is a pro-drug that was developed as a second generation in the thienopyridine 
class of P2Y12 inhibitors which bind irreversibly at the platelet ADP-binding site. Ticagrelor 
was subsequently developed as the first oral, reversible P2Y12 receptor antagonist with 
binding at a site that is distinct from the position of ADP-binding site. Ticagrelor has been 
found to have more consistent platelet inhibition than clopidogrel[3]. The PLATelet 
inhibition and patient Outcomes (PLATO, www.ClinicalTrials.gov ) trial showed that 
ticagrelor reduced the incidence of cardiovascular death, myocardial infarction and stroke 
compared to clopidogrel in patients with ST-elevation and non-ST-elevation acute coronary 
syndrome (ACS)[4]. In both treatment groups, the number of primary outcome events 
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increased over time, albeit more so with clopidogrel. Whether platelet adaptation to 
prolonged drug-induced inhibition was a contributing factor is unknown.
The purpose of our sub-study was to explore changes in platelet-related biomarkers over 
time that may represent an adaptation response and their association with clinical events 
among patients participating in the PLATO trial who received treatment with aspirin and 
either ticagrelor or clopidogrel.
Methods
The PLATO study (www.ClinicalTrials.gov ) has been described in detail previously[4, 5]. 
In brief, PLATO was a randomized, double-blind, double-dummy, parallel group, 
international, multicenter study with 18,624 participants. Patients with ACS were 
randomized to either clopidogrel or ticagrelor as soon as possible after admission and within 
24 hours of the presenting event. Patients who had already received a loading dose of 
clopidogrel were included in randomization and subsequently received treatment per study 
group protocol. Ticagrelor was given as a 180mg loading dose followed by 90mg twice 
daily. Clopidogrel was administered as a 75mg dose once daily. In patients not previously 
treated with clopidogrel, a 300mg loading dose was given and an additional 300mg was 
allowed prior to percutaneous coronary intervention (PCI); for patients on clopidogrel at 
baseline, a maintenance dose of 75mg of clopidogrel was given as the first dose. All patients 
received aspirin daily unless they were allergic or intolerant. Treatment was continued for a 
minimum of 6 months and up to 12 months.
Blood samples were collected from all patients participating in PLATO at randomization. A 
biomarker sub-study was also conducted in a group of patients who consented to additional 
blood tests and included a prospective evaluation with serial sampling in an effort to further 
elucidate underlying mechanisms correlating to clinical data. The three platelet-related 
biomarkers chosen were platelet count, soluble CD40-ligand (sCD40L) and soluble P-
selectin (sP-selectin). Platelet count was selected as a general measure of systemic 
conditions. sCD40-ligand was selected to represent the interface of platelets, thrombosis, 
and inflammation. Similarly, soluble P-selectin was chosen as a measure of platelet and 
endothelial cell activation. Platelet number, sCD40-ligand and soluble P-selectin were 
evaluated at baseline, hospital discharge, one month and six months from the time of study 
initiation. An initial evaluation of the PLATO biomarker data set did not reveal associations 
between baseline measures of platelet-related biomarkers and either primary or secondary 
outcomes at 1 year.
The current analysis is based on serial samples procured from patients enrolled in the 
PLATO biomarker sub-study who were on either clopidogrel or ticagrelor and had a valid 
baseline and two follow-up measurements for any biomarker. Blood samples were collected 
and analyzed at a central location. Platelet count was determined using an Electronic Cell 
Counter by Quintiles Laboratories. Soluble CD40L was analyzed using a Sandwich enzyme 
immunoassay (ELISA; Freedom EVOlyzer) using Human sCD40L kit (BenderMedSystems) 
at the UCR laboratory, Uppsala. Soluble P-selectin was analyzed using Sandwich enzyme 
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immunoassay (ELISA; Freedom EVOlyzer) using Human sP-selectin/CD62P kit (R&D 
Systems®) at the UCR laboratory, Uppsala.
A mixed model was used to estimate the short-term change rate (baseline to 1 month) and 
long-term change rate (1 month to 6 month) for each biomarker. We tested whether those 
change rates were different. We also tested if those change rates were different for patients 
treated with ticagrelor compared to patients with clopidogrel. The analyses were stratified 
according to the presence or absence of clopidogrel loading prior to randomization and 
baseline sampling.
A Cox proportional hazards model was used to evaluate the predictive utility of changes in 
biomarkers over time. Each biomarker was assessed against clinical endpoints of myocardial 
infarction, all-cause death, cardiovascular death, the composite of cardiovascular death, 
myocardial infarction or stroke, major bleeding, and non-CABG-related major bleeding. 
Hazard ratios (HR) were estimated for absolute changes in biomarkers for the baseline to 
one-month time period as a reflection of whether immediate changes after an ischemic event 
were predictive of outcomes. Similarly, hazard ratios were estimated for absolute changes in 
biomarkers for the one month to six-month time period as an indication of whether levels 
after recovery from an ischemic event were predictive of future events.
Results
Of the 18,624 patients in PLATO, a subset participated in the sub-study with 5693 patients 
who had a baseline and two follow-up measures of platelet count, 1897 with sCD40 ligand 
and 1898 with sP-selectin (Table 1). Prior to randomized treatment (baseline), sCD40 ligand 
and sP-selectin levels were elevated above the normal range of the assay (0.39 ug/L and 33.5 
ug/L, respectively). Platelet levels were within the normal range at 232 ×10E9/L.
When biomarker levels for all patients at one month – 0.35 ug/L and 29.1 ug/L for sCD40 
ligand and sP-selectin, respectively – were compared with baseline values, each had changed 
significantly (Table 2, p <0.0001). While platelet counts increased for all patients, levels of 
sCD40 ligand and sP-selectin both decreased (Figure 1). Additionally, patients treated with 
ticagrelor had a larger increase in platelet count compared to those treated with clopidogrel 
(Table 3a, p<0.0001). The rate of change for platelet count from baseline to one month also 
differed between treatment groups.
Similarly, when comparing biomarker levels for all patients at six months with those at one 
month, each differed significantly (Table 2; p<0.05). Platelet counts and sCD40 ligand 
decreased, while sP-selectin increased. However, there was no significant difference in 
change between treatment groups during this time period (Table 3b).
For each biomarker except sCD40 ligand, there was a significant difference in the rate of 
change between baseline to 1 month versus the 1 month to 6 month time points (p<0.0001). 
When the rate of change over both time periods was compared between treatment groups, 
there was a significantly greater change in platelet count during the acute phase from 
baseline to 1 month in the ticagrelor group. Both groups showed an increase in platelet 
count, but the rate of change was greater in patients who received ticagrelor versus 
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clopidogrel with a slope of 17.4 vs. 8.9 (p<0.0001) respectively (Table 4). This difference 
was no longer observed from 1 month to 6 months.
Clinical ischemic-thrombotic and hemorrhagic end point event rates were low overall in the 
PLATO population between the follow-up time points of 6 months and 1-year (Figure 2). 
Each biomarker was then assessed against ischemic-thrombotic and hemorrhagic clinical 
endpoints (Table 5). Platelet change from 1 month to 6 months was associated with 
ischemic-thrombotic events, including cardiovascular death, all-cause death and the 
composite of cardiovascular death, myocardial infarction or stroke. sCD40 ligand change 
from 1 month to 6 months was associated with hemorrhagic events. There were no 
differences between treatment groups for the associations with endpoints.
Discussion
Our study was an exploratory analysis of platelet-related biomarkers over time among 
patients with ACS. While there were dynamic changes, only platelet count was associated 
with ischemic-thrombotic events. The decrease in platelet count between the 1 and 6 month 
time points was associated with ischemic-thrombotic events but not with higher rates of 
bleeding. sCD40 ligand correlated directly with hemorrhagic events.
Because ticagrelor is a more potent platelet inhibitor than clopidogrel[3], one might 
hypothesize that it would elicit a more robust platelet adaptive response. While the rate of 
increase (slope) of platelet count was greater in the first month of treatment, whether this 
represents a marker of platelet adaptation is unknown. A prior analysis of data from the 
PLATO trial revealed that, in addition to lower platelet counts, there were lower levels of 
leukocytes and neutrophil sub-fractions in the clopidogrel group compared to the ticagrelor 
group[6]. This may reflect an off-target effect of the medication on bone marrow-derived 
progenitor cells in the clopidogrel group. As previously reported, the observations are not 
consistent with any off-target inhibitory effect of ticagrelor on the P2Y13 receptors, which 
are involved in pro-platelet formation, since this would be expected to lead to a lower 
platelet count compared to clopidogrel treatment[7].
The general concept of platelet adaptation in response to pharmacologic inhibition is 
biologically and teleologically plausible-perhaps even necessary to maintain hemostatic 
capacity. One might anticipate a platelet adaptome originating in megakaryocytes given their 
diversity and ability to respond at the molecular level to systemic conditions. Indeed, 
megakaryocyte adaptation has been observed after treatment with aspirin. Following 
administration of aspirin, there is an enhancement of the MRP4 expression, leading to 
decreased platelet inhibition by aspirin[8]. This does not exclude a platelet-specific adaptive 
transcriptome or proteome. In patients treated with aspirin daily, changes in platelet gene 
expression are seen as early as 2 weeks after initiation[2]. When inhibition of platelet 
reactivity is compared in patients after two months of treatment and two years of treatment, 
platelet aggregation is significantly higher at two years[9]. Similarly, impaired platelet 
inhibition to aspirin has been associated with platelet-specific genes and pathways that 
would predictably blunt the response to aspirin[10]. The aspirin response signature (ARS) is 
a group of 60 co-expressed genes, primarily of platelet origin, which has been shown to 
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correlate with platelet function. Although the genes are similarly co-expressed both before 
and after aspirin administration, the ARS was found to only correspond with the platelet 
function score following treatment with aspirin. This suggests an adaptive mechanism 
wherein the ARS genes are only apparent in the presence of COX-1 inhibition or aspirin 
causes a change in the genomics and protein signature of platelets.
Preservation of platelet function has also been studied in murine P2Y12 knock-out and 
heterozygous knock-down models. In vivo studies revealed an inability to form an occlusive 
thrombus, decreased thrombus stability and increased bleeding times in knock-out mice 
while heterozygous mice had preserved bleeding times[11, 12]. In humans with deficiency 
of platelet P2Y12 receptors or loss-of-function mutations of the P2Y12 receptor gene, there is 
typically a mild bleeding phenotype[11, 12]. Given these observations, several different in 
vivo experiments have been performed to better understand the underlying mechanism(s) of 
adaptation. For example, while knock-out mice have decreased response to collagen and 
murine-TRAP, at high concentrations the response is similar to wild-type mice indicating a 
shift, rather than a lack, in the concentration-response. In addition, heterozygous mice have 
been found to have similar repression of cAMP levels by ADP to wild-type mice; thus even 
50% of the level of the P2Y12 receptor remains sufficient to mediate inhibition of adenylyl 
cyclase, indicating presence of an innate redundancy[12].
The PLATO sub-study cohort and serial sampling provided an opportunity to test, in 
principle, our exploratory hypothesis. However, we acknowledge several limitations. While 
sCD40 ligand and sP-selectin are markers of platelet activation, they are not platelet-
specific. sCD40 ligand is present within activated platelets and T cells; changes in levels can 
be seen in a number of clinical conditions characterized by inflammation and thrombosis; 
and the clinical utility of these measures is unknown. The optimal platelet-related biomarker 
to determine adaptive responses to either short-or long-term pharmacologic inhibition is yet 
to be determined, but is likely of megakaryocyte origin and is reflected in the platelet 
proteome or secretome.
In conclusion, dynamic changes in platelet count, CD-40 ligand and soluble P-selectin occur 
over time among patients with ACS. Platelet count and sCD40 ligand may offer modest 
overall predictive value for future ischemic-thrombotic or hemorrhagic clinical events, 
respectively. Platelet-directed therapy with a P2Y12 receptor inhibitor in combination with 
aspirin modestly impacts the expression of these biomarkers. The existence of a platelet 
adaptome and its overall clinical significance among patients at risk for thrombotic events 
will require a more in-depth and platelet-biology specific investigation.
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Figure 1. 
Change of each biomarker over time periods studied. Delta 1 represents value at 1 month 
minus baseline and delta 2 value at 6 months minus 1 month.
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Figure 2. 
Kaplan-Meier Event rates in the PLATO population between 6 months and 1-year
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Table 1.
Baseline Characteristics by Biomarker-Defined Populations
Populations
Characteristic
Plato Population 
(N=18624)
Platelet Subgroup 
(N=5963)
CD 40 Subgroup 
(N=1897)
sP-Selectin Subgroup 
(N=1898)
Female Gender 5288 / 18624 (28.4%) 1660 / 5963 (27.8%) 533 / 1897 (28.1%) 534 / 1898 (28.1%)
Age, years (Median, 
25th-75th)
62 (54–71) 62 (54–70) 61 (53–70) 61 (53–70)
Body Mass Index, (Median, 
25th-75th)
27.4 (24.7–30.4) 27.5 (24.9–30.5) 27.7 (25.0–30.9) 27.7 (25.1–30.9)
Systolic Blood Pressure, 
mmHg (Median, 25th-75th)
133 (120–150) 133 (120–150) 135 (120–150) 135 (120–150)
Diastolic Blood Pressure, 
mmHg (Median, 25th-75th)
80 (70–90) 80 (70–90) 80 (70–90) 80 (70–90)
Heart Rate, bpm (Median, 
25th-75th)
73 (64–84) 72 (64–82) 72 (63–82) 72 (63–82)
Medical History
Myocardial Infarction 3824 / 18613 (20.5%) 1163 / 5963 (19.5%) 379 / 1897 (20.0%) 379 / 1898 (20.0%)
Coronary Artery Disease 5126 / 18613 (27.5%) 1580 / 5963 (26.5%) 542 / 1897 (28.6%) 543 / 1898 (28.6%)
Percutaneous Coronary 
Intervention
2492 / 18612 (13.4%) 788 / 5963 (13.2%) 234 / 1897 (12.3%) 234 / 1898 (12.3%)
Coronary Artery Bypass Graft 1106 / 18613 (5.9%) 330 / 5963 (5.5%) 84 / 1897 (4.4%) 84 / 1898 (4.4%)
Transient Ischemic Attack 499 / 18613 (2.7%) 156 / 5963 (2.6%) 39 / 1897 (2.1%) 39 / 1898 (2.1%)
Non-Hemorrhagic Stroke 722 / 18612 (3.9%) 203 / 5963 (3.4%) 69 / 1897 (3.6%) 69 / 1898 (3.6%)
Hypertension 12183 / 18613 (65.5%) 3822 / 5963 (64.1%) 1255 / 1897 (66.2%) 1256 / 1898 (66.2%)
Diabetes 4662 / 18613 (25.0%) 1393 / 5963 (23.4%) 423 / 1897 (22.3%) 424 / 1898 (22.3%)
Dyslipidemia 8689 / 18612 (46.7%) 2765 / 5962 (46.4%) 811 / 1897 (42.8%) 812 / 1898 (42.8%)
Gastrointestinal Bleeding 265 / 18613 (1.4%) 86 / 5963 (1.4%) 24 / 1897 (1.3%) 24 / 1898 (1.3%)
Chronic Renal Disease 785 / 18613 (4.2%) 190 / 5963 (3.2%) 57 / 1897 (3.0%) 57 / 1898 (3.0%)
Treatment Approach
 Invasive 13408 / 18624 (72.0%) 4200 / 5963 (70.4%) 1353 / 1897 (71.3%) 1353 / 1898 (71.3%)
 Medically Managed 5216 / 18624 (28.0%) 1763 / 5963 (29.6%) 544 / 1897 (28.7%) 545 / 1898 (28.7%)
STEMI at presentation 7544 / 18618 (40.5%) 2392 / 5963 (40.1%) 832 / 1897 (43.9%) 832 / 1898 (43.8%)
Aspirin at time of 
randomization
17428 / 18601 (93.7%) 5575 / 5963 (93.5%) 1817 / 1897 (95.8%) 1818 / 1898 (95.8%)
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Table 2:
Summary of Biomarker Changes: For All Patients
Characteristic 1 Month - Baseline
p-value 1
1 Mon Vs. Baseline 6 Month - 1 Month
p-value 2
6 Mon Vs. 1 Mon
Platelet (x10E9/L) N: Median 
(25th-75th)
5963: 6.0 (−21.0–35.0) <.0001 5963: −1.0 (−27.0–22.0) <.0001
CD40 (ug/L) N: Median (25th-75th) 1897: −0.04 (−0.27–0.13) <.0001 1897: −0.01 (−0.22–0.17) 0.0188
P-Selectin (ug/L) N: Median 
(25th-75th)
1898: −4.4 (−13.0–3.7) <.0001 1898: 1.3 (−5.8–8.4) <.0001
J Thromb Thrombolysis. Author manuscript; available in PMC 2019 September 14.
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
Lo
w
en
stern et al.
P
age 13
Table 3:
Change of Biomarkers over each Time Period by Treatment Group
Table 3a. Baseline to 1 Month by Treatments
Characteristic
Overall Levels at 1 Month
Change in Biomarker Level
Overall Clopidogrel Ticagrelor p-value
Platelet (x10E9/L) N: Median (25th-75th) 5963: 239.0 (200.0 – 288.0) 5963: 6.0 (−21.0–35.0) 2985: 1.0 (−23.0–31.0) 2978: 10.0 (−16.0–39.0) <.0001
CD40 (ug/L) N: Median (25th-75th) 1897: 0.35 (0.14 – 0.72) 1897: −0.04 (−0.27–0.13) 973: −0.03 (−0.26–0.14) 924: −0.04 (−0.30–0.12) 0.5852
P-Selectin (ug/L) N: Median (25th-75th) 1898: 29.1 (22.5 – 37.3) 1898: −4.4 (−13.0–3.7) 974: −4.3 (−13.6–3.1) 924: −4.4 (−12.6–4.2) 0.2719
Table 3b. 1 Month to 6 Month by Treatments
Characteristic
Overall Levels at 6 Months
Change in Biomarker Level
Overall Clopidogrel Ticagrelor p-value
Platelet (x10E9/L) N: Median (25th-75th) 5963: 237.0 (201.0 – 278.0) 5963: −1.0 (−27.0–22.0) 2985: 0.0 (−26.0–21.0) 2978: −1.0 (−28.0–22.0) 0.9115
CD40 (ug/L) N: Median (25th-75th) 1897: 0.31 (0.12 – 0.74) 1897: −0.01 (−0.22–0.17) 973: −0.02 (−0.24–0.19) 924: −0.01 (−0.20–0.17) 0.7871
P-Selectin (ug/L) N: Median (25th-75th) 1898: 30.1 (23.1 – 39.3) 1898: 1.3 (−5.8–8.4) 974: 1.5 (−5.5–8.4) 924: 1.2 (−6.1–8.4) 0.4223
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Table 4:
Rate of Change of Biomarkers over each Time Period
Biomarkers
Slope (Rate of change per month) Estimate 95% Confidence Limit
P value for 
different slopes
P value for 
interaction with 
treatment
Platelet Count Slope 1: Baseline to 1M <.0001 <.0001
 Ticagrelor 17.4040 (15.316, 19.492)
 Clopidogrel 8.9605 (6.8754, 11.046)
Slope 2: 1Mth to 6M 0.8663
 Ticagrelor −1.5535 (−1.971, −1.136)
 Clopidogrel −1.5028 (−1.920, −1.086)
CD40 Ligand Slope 1: Baseline to 1M −0.04948 (−.1118, 0.0128) 0.1828 0.7730
Slope 2: 1Mth to 6M −0.00233 (−.0148, 0.0101) 0.5342
P-Selectin Slope 1: Baseline to 1M −4.9842 (−6.039, −3.929) <.0001 0.4251
Slope 2: 1Mth to 6M 0.3676 (0.1566, 0.5785) 0.2076
J Thromb Thrombolysis. Author manuscript; available in PMC 2019 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lowenstern et al. Page 15
Table 5:
Changes in Platelet-Related Biomarkers and Their Association with Clinical Outcomes from Cox proportional 
hazards models
Outcome Biomarker changes
Hazard 
Ratio
95% Lower 
Confidence Limit 
for Hazard Ratio
95% Upper 
Confidence Limit 
for Hazard Ratio P Value
CVD/MI/Stk Platelet:change per 100 from BL to 1M 1.195 0.846 1.687 0.3119
Platelet:change per 100 from 1m to 6 M 1.512 1.094 2.090 0.0122
CD40:change from BL to 1 M 0.914 0.591 1.414 0.6865
CD40:change from 1m to 6 M 1.128 0.967 1.317 0.1252
Selectin:change per 100 from BL to 1M 0.106 0.009 1.297 0.0789
Selectin:change per 100 from 1m to 6 M 0.494 0.077 3.181 0.4576
CV Death Platelet:change per 100 from BL to 1M 1.265 0.804 1.989 0.3090
Platelet:change per 100 from 1M to 6M 1.972 1.323 2.939 0.0008
CD40:change from BL to 1M 0.683 0.343 1.359 0.2768
CD40:change from 1M to 6M 1.180 0.946 1.472 0.1425
Selectin:change per 100 from BL to 1M 0.020 0.000 1.523 0.0768
Selectin:change per 100 from 1M to 6M 0.226 0.009 5.873 0.3709
All Cause Death Platelet:change per 100 from BL to 1M 1.373 0.912 2.068 0.1287
Platelet:change per 100 from 1M to 6M 2.232 1.547 3.219 <.0001
CD40:change from BL to 1M 0.683 0.343 1.359 0.2768
CD40:change from 1M to 6M 1.180 0.946 1.472 0.1425
Selectin:change per 100 from BL to 1M 0.020 0.000 1.523 0.0768
Selectin:change per 100 from 1 M to 6M 0.226 0.009 5.873 0.3709
MI Platelet:change per 100 from BL to 1M 1.247 0.778 1.999 0.3581
Platelet:change per 100 from 1 M to 6M 1.537 0.980 2.412 0.0612
CD40:change from BL to 1M 1.155 0.852 1.566 0.3541
CD40:change from 1M to 6M 1.126 0.889 1.427 0.3256
Selectin:change per 100 from BL to 1M 1.519 0.111 20.798 0.7541
Selectin:change per 100 from 1M to 6M 1.337 0.205 8.700 0.7614
Major Bleeding Platelet:change per 100 from BL to 1M 1.390 0.882 2.188 0.1556
Platelet:change per 100 from 1M to 6M 1.661 1.047 2.634 0.0312
CD40:change from BL to 1M 0.929 0.481 1.794 0.8269
CD40:change from 1M to 6M 1.396 1.174 1.660 0.0002
Selectin:change per 100 from BL to 1M 0.583 0.031 10.907 0.7183
Selectin:change per 100 from 1M to 6M 1.236 0.193 7.927 0.8230
Non-CABG Major 
Bleeding
Platelet:change per 100 from BL to 1M 2.224 1.357 3.645 0.0015
Platelet:change per 100 from 1M to 6M 1.669 0.996 2.797 0.0518
CD40:change from BL to 1M 0.322 0.047 2.188 0.2462
CD40:change from 1M to 6M 1.299 1.058 1.594 0.0124
Selectin:change per 100 from BL to 1M 0.257 0.003 25.705 0.5635
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Outcome Biomarker changes
Hazard 
Ratio
95% Lower 
Confidence Limit 
for Hazard Ratio
95% Upper 
Confidence Limit 
for Hazard Ratio P Value
Selectin:change per 100 from 1M to 6M 0.385 0.006 26.732 0.6591
Adjustments made for baseline biomarkers, baseline treatment, on/off drug at 6 month and all the covariates in baseline model.
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